Welcome to the October 2018 edition of our Updates on Myeloproliferative Neoplasms (MPNs) newsletter. This month, we highlight the latest research and discussion on treating and managing polycythemia vera (PV), including the use of cytoreductive therapy for high-risk PV and patient-reported outcomes on symptom burden and quality of life from the REVEAL study. We also explore an overview of combination therapies with potential benefit for patients with ruxolitinib-refractory myelofibrosis (MF), and 12-month follow-up data from the COMBI trial of pegylated interferon alfa-2 plus ruxolitinib in patients with MF or PV. Additionally, we feature a review on the importance of identifying blood clots as a possible early symptom of essential thrombocythemia.
If you haven’t yet, make sure to watch our roundtable panel discussion, “Management of Myeloproliferative Neoplasms: A Case-Based Discussion,” on the current state of MPN treatment and management. You can also learn more about MPN diagnosis and management by checking out my patient interview and our helpful “fast facts” guides.
Please feel free to share this newsletter with your colleagues, and don’t hesitate to get in touch with me with comments or suggestions through the JADPRO editors at email@example.com at any time.
Lindsey Lyle, MS, PA-C
Senior Instructor, Blood Cancers and Bone Marrow Transplant Program
University of Colorado, Anschutz Medical Campus